For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Natalizumab | Participants in this group are those who opt to receive treatment with natalizumab IV 300mg/day given q 4 weeks for 48 weeks. Natalizumab | 0 | None | 0 | 4 | 2 | 4 | View |
| Control | Participants in this group may initiate any FDA approved DMT at any time post delivery or remain on no therapy. | 0 | None | 0 | 26 | 7 | 26 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| MS relapse | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |